Author: Marie Jones

CStone Pharmaceuticals (“CStone”; Stock Code: 2616.HK), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and molecularly-targeted precision medicines for the treatment of cancer, today released its audited annual financial results for the year ended December 31, 2019. “2019 was a transformational year for the company as we continued to advance the development of our IO and precision medicine products. Among the multiple critical milestones achieved, we initiated 9 new pivotal studies, for a total of 13 registration studies that are ongoing,” said Dr. Frank Jiang, Chairman and Chief Executive Officer of CStone. “In 2019, we…

Wintermar Offshore Marine (WINS:JK) has reported results for the 2019 financial year, with a smaller Net Loss of US$13.3 million for FY2019, a drop of 48% from the previous year, as utilization picked up consistently throughout the year. In line with fleet utilization which recovered from 46% in 1Q2019 to 77% by 4Q2019, revenue continued to pick up on a quarterly basis, totaling US$15 million in Q42019 from US$14.6 million the previous quarter. This was driven by high tier utilization which reached 85% in 4Q2019. *Owned Vessel Division FY2019 started poorly as the Presidential elections in Indonesia caused delays in…

AIM ImmunoTech(NYSE-American交易代码: AIM)今天宣布，它正在积极寻找研究人员和地点进行安普利近的临床测试，测试其作为由SARS-CoV-2新型冠状病毒引发的新型肺炎的保护性预防和早期疗法的疗效。 该公司将临床试验目标选定在美国、欧洲、亚洲和阿根廷，并且作为临床试验开始前的必要步骤，目前公司正在征集一个或多个国家和地区的一个或多个地点以及符合资质的首席研究员。潜在临床试验的医疗方案已处于研发的最后阶段。接下来AIM打算寻求机构审查委员会的批准和政府授权，以尽快开始进行将安普利近作为保护性预防和早期疗法的临床试验。 在过去两个月中，AIM已达到几个重要的新冠肺炎里程碑： – 在寻求国内外研究合作伙伴之前，AIM提交了临时专利申请来保护公司的知识产权。 – 日本国立传染病研究所(NIID)同意将安普利近作为新冠肺炎的潜在治疗药物进行试验。测试和研究将在NIID和东京大学的实验室中进行。 AIM会在收到结果后立即报告。 – AIM与“中国走出去”网站(CGA)合作，以促进安普利近在中华人民共和国(PRC)的临床前及临床试验。 – AIM正在与阿根廷的GP-Pharm进行商谈，以推进安普利近对抗新冠肺炎的潜在用途。在阿根廷境内，安普利近是一种获准用于治疗肌痛性脑脊髓炎/慢性疲劳综合征的药物。 – AIM正在与myTomorrows和鹿特丹大学医学院(Erasmus MC)进行讨论——目前它们将安普利近用于胰腺癌患者的治疗，以探索对安普利近进行快速临床前和临床试验。 “自疫情爆发以来，我们一直致力于研发安普利近，期待其成为这种高致病性冠状病毒的鼻内和口服保护性预防药物以及静脉注射早期治疗药物。”AIM首席执行官Thomas K. Equels表示。 “世界各地站在抗击这一流行病前线的工作人员清楚，他们的家人也同样明白，他们每天都在冒着生命危险与新冠肺炎病人打交道。例如，在西班牙报告的病例中，医护人员感染比例高达13%。我的一个儿子和一个外甥是医生，一个女儿和一个妹妹在做护士，三个侄子是急救人员，还有一个侄子是警察。这场斗争对我而言是一场个人的战斗，全世界无数人也面临与我一样的境况。在缺乏有效疫苗的情况下，研发如安普利近之类的早期治疗药物，可能对一线工作人员的健康和遏制大流行的蔓延都意义非凡。” AIM还在继续等待六项正在进行的临床试验的结果，这些临床试验研究了安普利近对不同类型癌症的疗效，目前实验还在稳步推进中。随着更多关于这些研究的信息披露，公司也会及时将最新信息告知股东和市场。为此，该公司今天向罗斯威尔帕克综合癌症中心(Roswell Park Comprehensive Cancer Center)提交了一份《材料调拨和研究协议》的适时执行修正案，并附有一份展示正在进行或即将进行的临床试验的证明。癌症患者是新冠肺炎的易感人群。我们还认识到，与所有医疗机构一样，所有的癌症中心也都必须对这一流行病进行一级响应。因此，鉴于新冠肺炎的医疗应急状况，癌症患者正在进行的临床实验登记和报告可能会出现延迟。 关于AIM ImmunoTech公司 AIM ImmunoTech公司是一家免疫制药公司，专门从事治疗免疫疾病、病毒性疾病和多种癌症的疗法的研究和开发。AIM的主打产品包括阿根廷批准的药物rintatolimod(商品名安普利近®或Rintamod®)和FDA批准的药物Alferon N Injection®。根据已发表的同行评审的临床前研究和临床试验结果，AIM认为安普利近®可能具有广谱抗病毒和抗癌特性。安普利近®的临床试验包括对肾癌、恶性黑色素瘤、结直肠癌、晚期复发性卵巢癌和三阴性转移性乳腺癌患者的研究。这些和其他潜在用途需要额外的临床试验，确认支持监管批准和额外资金所需的安全性和有效性数据。Rintatolimod是一种双链RNA，开发用于治疗全球重要的削弱免疫系统的疾病和失调。 警告性声明 本新闻稿中包含1995年《私人证券诉讼改革法》所指的前瞻性陈述，诸如“可能”、“将会”、“预期”、“计划”、“预计”等词语和类似的表达(以及其他提及未来事件或情况的词语或表达) ，旨在标识前瞻性陈述。这些声明涉及许多风险和不确定性。例如，需要进行大量的额外测试和试验才能确定安普利近是否能有效治疗人类感染的新冠肺炎，但不能保证能成功。部分世界上首屈一指的大型制药公司都正在竞相寻找治疗新冠肺炎的药物。即使实验证明安普利近可以有效抗击病毒，也不能保证我们证明其疗效的相关行动可获得优先权。又或者即使安普利近被证明是有效的，但如果出现另一种最终证明同样有效的治疗方案，我们的努力也有前功尽弃的风险。不能保证未来的研究不会得出与参考研究报告不同的结论。另外在海外国家开展业务存在诸多风险，包括在执行知识产权方面的潜在困难。我们无法保证我们在国外的潜在业务不会受到这些风险的不利影响。关于公司与安普利近的合作活动，无法保证目前或计划中的试验是否会成功或产生有利的数据，而且试验受到许多因素的影响，包括缺乏监管机构的批准、缺乏研究药物或赞助其他试验的机构的优先次序变动。此外，许多因素可能导致计划的临床试验无法启动，包括缺乏监管批准或缺乏研究药物。即使这些临床试验得以启动，我们也无法保证临床研究会成功或产生任何有用的数据或需要额外的资金。本文中所载的任何前瞻性陈述仅在本报告之日起生效。公司不承诺更新任何前瞻性声明，以反映在此日期之后发生的事件或情况。本文稿并不会参考本网站所载的资料，只供参考之用。 联系人: Crescendo Communications, LLC 电话: 212-671-1021 电子邮件: aim@crescendo-ir.com AIM ImmunoTech Inc 电话: 800-778-4042 电子邮件: IR@aimimmuno.com 资料来源: AIM ImmunoTech Inc.

AIM ImmunoTech(NYSE-American交易代碼: AIM)今天宣布，它正在積極尋找研究人員和地點進行安普利近的臨床測試，測試其作為由SARS-CoV-2新型冠狀病毒引發的新型肺炎的保護性預防和早期療法的療效。 該公司將臨床試驗目標選定在美國、歐洲、亞洲和阿根廷，並且作為臨床試驗開始前的必要步驟，目前公司正在徵集一個或多個國家和地區的一個或多個地點以及符合資質的首席研究員。潛在臨床試驗的醫療方案已處於研發的最後階段。接下來AIM打算尋求機構審查委員會的批准和政府授權，以盡快開始進行將安普利近作為保護性預防和早期療法的臨床試驗。 在過去兩個月中，AIM已達到幾個重要的新冠肺炎里程碑： – 在尋求國內外研究合作夥伴之前，AIM提交了臨時專利申請來保護公司的知識產權。 – 日本國立傳染病研究所(NIID)同意將安普利近作為新冠肺炎的潛在治療藥物進行試驗。測試和研究將在NIID和東京大學的實驗室中進行。 AIM會在收到結果後立即報告。 – AIM與“中國走出去”網站(CGA)合作，以促進安普利近在中華人民共和國(PRC)的臨床前及臨床試驗。 – AIM正在與阿根廷的GP-Pharm進行商談，以推進安普利近對抗新冠肺炎的潛在用途。在阿根廷境內，安普利近是一種獲准用於治療肌痛性腦脊髓炎/慢性疲勞綜合徵的藥物。 – AIM正在與myTomorrows和鹿特丹大學醫學院(Erasmus MC)進行討論——目前它們將安普利近用於胰腺癌患者的治療，以探索對安普利近進行快速臨床前和臨床試驗。 “自疫情爆發以來，我們一直致力於研發安普利近，期待其成為這種高致病性冠狀病毒的鼻內和口服保護性預防藥物以及靜脈注射早期治療藥物。”AIM首席執行官Thomas K . Equels表示。 “世界各地站在抗擊這一流行病前線的工作人員清楚，他們的家人也同樣明白，他們每天都在冒著生命危險與新冠肺炎病人打交道。例如，在西班牙報告的病例中，醫護人員感染比例高達13%。我的一個兒子和一個外甥是醫生，一個女兒和一個妹妹在做護士，三個侄子是急救人員，還有一個侄子是警察。這場鬥爭對我而言是一場個人的戰鬥，全世界無數人也面臨與我一樣的境況。在缺乏有效疫苗的情況下，研發如安普利近之類的早期治療藥物，可能對一線工作人員的健康和遏制大流行的蔓延都意義非凡。” AIM還在繼續等待六項正在進行的臨床試驗的結果，這些臨床試驗研究了安普利近對不同類型癌症的療效，目前實驗還在穩步推進中。隨著更多關於這些研究的信息披露，公司也會及時將最新信息告知股東和市場。為此，該公司今天向羅斯威爾帕克綜合癌症中心(Roswell Park Comprehensive Cancer Center)提交了一份《材料調撥和研究協議》的適時執行修正案，並附有一份展示正在進行或即將進行的臨床試驗的證明。癌症患者是新冠肺炎的易感人群。我們還認識到，與所有醫療機構一樣，所有的癌症中心也都必須對這一流行病進行一級響應。因此，鑑於新冠肺炎的醫療應急狀況，癌症患者正在進行的臨床實驗登記和報告可能會出現延遲。 關於AIM ImmunoTech公司 AIM ImmunoTech公司是一家免疫製藥公司，專門從事治療免疫疾病、病毒性疾病和多種癌症的療法的研究和開發。 AIM的主打產品包括阿根廷批准的藥物rintatolimod(商品名安普利近®或Rintamod®)和FDA批准的藥物Alferon N Injection®。根據已發表的同行評審的臨床前研究和臨床試驗結果，AIM認為安普利近®可能具有廣譜抗病毒和抗癌特性。安普利近®的臨床試驗包括對腎癌、惡性黑色素瘤、結直腸癌、晚期復發性卵巢癌和三陰性轉移性乳腺癌患者的研究。這些和其他潛在用途需要額外的臨床試驗，確認支持監管批准和額外資金所需的安全性和有效性數據。 Rintatolimod是一種雙鏈RNA，開髮用於治療全球重要的削弱免疫系統的疾病和失調。 警告性聲明 本新聞稿中包含1995年《私人證券訴訟改革法》所指的前瞻性陳述，諸如“可能”、“將會”、“預期”、“計劃”、“預計”等詞語和類似的表達(以及其他提及未來事件或情況的詞語或表達) ，旨在標識前瞻性陳述。這些聲明涉及許多風險和不確定性。例如，需要進行大量的額外測試和試驗才能確定安普利近是否能有效治療人類感染的新冠肺炎，但不能保證能成功。部分世界上首屈一指的大型製藥公司都正在競相尋找治療新冠肺炎的藥物。即使實驗證明安普利近可以有效抗擊病毒，也不能保證我們證明其療效的相關行動可獲得優先權。又或者即使安普利近被證明是有效的，但如果出現另一種最終證明同樣有效的治療方案，我們的努力也有前功盡棄的風險。不能保證未來的研究不會得出與參考研究報告不同的結論。另外在海外國家開展業務存在諸多風險，包括在執行知識產權方面的潛在困難。我們無法保證我們在國外的潛在業務不會受到這些風險的不利影響。關於公司與安普利近的合作活動，無法保證目前或計劃中的試驗是否會成功或產生有利的數據，而且試驗受到許多因素的影響，包括缺乏監管機構的批准、缺乏研究藥物或贊助其他試驗的機構的優先次序變動。此外，許多因素可能導致計劃的臨床試驗無法啟動，包括缺乏監管批准或缺乏研究藥物。即使這些臨床試驗得以啟動，我們也無法保證臨床研究會成功或產生任何有用的數據或需要額外的資金。本文中所載的任何前瞻性陳述僅在本報告之日起生效。公司不承諾更新任何前瞻性聲明，以反映在此日期之後發生的事件或情況。本文稿並不會參考本網站所載的資料，只供參考之用。 聯繫人: Crescendo Communications, LLC 電話: 212-671-1021 電子郵件: aim@crescendo-ir.com AIM ImmunoTech Inc 電話: 800-778-4042 電子郵件: IR@aimimmuno.com 資料來源: AIM ImmunoTech Inc.

Targets Investments in US$10M to US$50M Range Initially Yamada Consulting Group Co., Ltd. (“YCG”) of Japan and ZICO Holdings Inc. (“ZICO”) announced today they would offer a joint platform for advisory and consulting services to bridge a major funding gap between Japanese investors and ASEAN small and medium enterprises (“SMEs”), with initial target funding of between US$10 to US$50 million each. The Strategic Collaboration Agreement was signed by Mr Keisaku Masuda, President and CEO of YCG, a leading independent consulting group based in Japan which is listed on the First Section of the Tokyo Stock Exchange, and Mr Chew Seng…

Total Revenue up 15.6% to approximately RMB71.3 million with RMB2.03 cents of Final Dividend; Shows a Prominent Sustainable Development Everbright Grand China Assets Limited (“Everbright Grand China” or the “Group”; HKEX stock code: 03699), a subsidiary of China Everbright Group, principally engaged in the businesses of property leasing, property management and sales of properties held for sale, announced its annual results for the year ended 31 December 2019 (“the year under review”). In 2019, despite a challenging operating environment, the group achieved satisfactory operating results in its efforts to further increase the value of its properties and revenue from its…

“Fans await with high expectations for the #TwitterBlueroom Live Q&A with Suho” – Suho of EXO is set to hold a live Q&A session on #TwitterBlueroom to celebrate the release of his first EP, “Self-Portrait” – Suho will unbox his album for the first time live on #TwitterBlueroom – Winning submissions from # [*1] (Drawing Contest for the World’s Best Suho) will also be announced and featured Twitter Korea will host a ‘live’ #TwitterBlueroom Q&A session with Suho, member of the popular Kpop boy band EXO (@weareoneEXO), on March 26th at 6PM KST. A special emoji has been created in…

Redsun Properties Group Limited (“Redsun Properties”, or the “Group”, stock code: 1996), a leading comprehensive property developer in Mainland China, announced its annual results for the year ended 31 December 2019. The Group maintained a healthy financial position under its “Property + Commercial” dual-driven strategy, which helped it realise synergies and build diversified competitiveness. Results Highlights: – Business continued to grow under the Group’s “Property + Commercial” dual-driven strategy. Contracted sales amounted to RMB65.15 billion in 2019, surging around 37.6%. – Net profit strongly increased by 23.6% to RMB1.64 billion. Net profit margin was 10.8% – Recommended the payment of…

Cheer for the Hong Kong athletes who are prepping for the Olympic Games at Tokyo! Nissin Foods (Stock code: 1475) announced the company will join the chorus to support these local elite athletes through team-up with the Sports Federation & Olympic Committee of Hong Kong, China (SF&OC) as the “Exclusive Food Partner of Hong Kong, China’s Delegation to the Tokyo 2020 Olympic Games.” Although the Tokyo Olympics is postponed due to the epidemic, which has greatly affected the training schedule of athletes, by adhering to its corporate slogan of “HUNGRY to WIN”, Nissin Foods has decided to embrace the challenges…

EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, stock code: 1846), is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and 25 years of experience with individualised customer-care and principally engaged in the provision of vision correction services in Germany, Denmark and the People’s Republic of China (“the PRC”). 2019 Annual Results Highlights – Total Revenue for the year 2019 reached approximately EUR49 million, up approximately 14% YoY – Gross Profit for the year 2019 reached approximately EUR20.3 million, up approximately 16.3% YoY – Adjusted Gross Profit1 for the year 2019 was…

Registered Users of Flagship Product Warframe Maintains Growth Momentum; Total Revenue Reached US$214.2 million The global market leader in free-to-play multiplayer online games, Leyou Technologies Holdings Limited (“Leyou Technologies”, and its subsidiaries collectively “the Group”; stock code: 1089) is pleased to announce its annual results for the year ended 31 December 2019 ( the “reporting period”). During the reporting period, total revenue of the Group slightly decreased by 5.9% to US$214.2 million. Gross profit amounted to US$121.8 million (2018: US$141.5 million). The Group’s EBITDA was US$49.6 million (2018: US$67.0 million). Nevertheless, excluding non-recurring items of impairment losses and equity-settled shared-based…

TOKYO – (ACN Newswire) – On March 6th Azabu Insights proposed a theory that coronavirus seemed to be spreading faster in cold countries than in warm countries. We followed this up with an update on March 11th showing that at that time the data was showing ninety-eight percent of the cases were all in cold countries. Since then we have had many comments from different people. One very respected business person who works in life sciences, told us he thought it was a, “multivariate problem,” and suggested that, “It’s possible, for example, that infection rate would be strongly correlated with people meeting in enclosed…

Gave priority to business quality; Delivered solid business results; Sustained increase in overall strength China Pacific Insurance (Group) Co., Ltd. (the “CPIC” or the “Group”; Stock code: 2601.HK, 601601.SH) is pleased to announce the annual results of the Group for 2019. The year 2019 was special in many ways. It marked the 70th anniversary of the founding of the People’s Republic of China, represented a critical period in China’s effort to build itself into an all-around moderately prosperous society, and marked the 3rd fiscal year of the 8th Board of Directors of CPIC. In the past 3 years, the board…

Office Software and Services Business Achieves Breakthroughs; Cloud Services Further Expand Leveraging New Technologies Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its 2019 unaudited annual results and fourth quarter results for the period ended 31 December 2019. For the year of 2019, the revenue of Kingsoft increased 39% year-on-year to RMB8,218.3 million. Revenue from the online games, cloud services and office software and services and others represented 33%, 47% and 20%, respectively, of the Company’s total revenue for the year of 2019. For the fourth quarter…

VCREDIT Holdings Limited (“VCREDIT” or the “Group”; stock code: 2003.HK), a leading independent online consumer finance provider in China, is pleased to announce its audited consolidated annual results for the 12 months ended 31 December 2019 (“the Year”). During the Year, the Group’s total income increased by 41.2% to RMB3,864.4 million, underpinned by the Group’s strategy to shift completely to a pure online consumer finance platform while transitioning to a more balanced funding split between direct lending, trust lending and loan facilitation. 40.4% new registered users increased during the Year. The Group’s highly automated and intelligent credit and risk management…

Revenue Achieved Surge by 58.6%, Proceed with Hospital Group Business The board (the “Board”) of directors (the “Directors”) of Genertec Universal Medical Group Company Limited (the “Company” or “Universal Medical”) is pleased to announce the annual results of the Company and its subsidiaries (together, the “Group”) for the year ended 31 December 2019. 2019 ANNUAL RESULTS HIGHLIGHTS – The revenue amounted to approximately RMB6,815.6 million, representing an increase of 58.6% as compared with that of approximately RMB4,296.9 million for 2018. – The profit before tax amounted to approximately RMB2,211.9 million, representing an increase of 19.0% as compared with that of…

Total Attributable Contracted Sales to Be Booked Exceeds HK$10 billion; Laying a Solid Foundation for its Profit in the Future K. Wah International Holdings Limited (“KWIH” or “the Group”) (stock code: 00173) has today announced its annual results for the year ended 31 December 2019. Adhering to its commitment to “Quality and Excellence”, the Group launched its premium projects based on its prudent approach during the year under review and recorded satisfactory sales results, mainly from K. City in Hong Kong, The Palace III – Le Haut and Windermere in Shanghai, The Peak in Nanjing and J Metropolis in Guangzhou.…

Mar 24, 2020 – Cybozu, Inc., the kintone collaboration platform developer used by 9 million people worldwide, held a presentation on February 25, 2020 to announce its financial results for the previous fiscal year, as well as its business strategy for the current fiscal year highlighting its steady business performance and its future strategy for strengthening the sales system for kintone, Cybozu’s flagship product, in the Asia Pacific region. In January 2020, a new Business Strategy Office was established to strengthen the global deployment of Cybozu’s sales expansion. In particular, kintone, a cloud-based app for work improvement, is seeing steady sales…

Adjusted Net Profit Increases by 28.4% to HK$91.9 Million; Final Dividend of HK9.0 Cents per Share Q P Group Holdings Limited (“Q P Group” or the “Group”; Stock code: 01412 ), the largest producer of paper-based tabletop games and related products and the second-largest producer of paper-based greeting cards in the PRC#, announced today the first annual results of the Group after its listing on the Main Board of The Stock Exchange of Hong Kong Limited on 16 January 2020. During the year ended 31 December 2019, the Group recorded a profit attributable to equity holders of the Company of…

Tianyun International Holdings Limited (“Tianyun International”, together with its subsidiaries, the “Group”, Stock code: 6836.HK), a leading seller and manufacturer of processed fruits products in China, is pleased to announce, upon the easing of the coronavirus disease 2019 (“COVID-19”) outbreak in China, to echo with the Government’s initiative of “Progressive Resumption of Production”, the Group’s production and operations have gradually resumed since late February. The Group’s production bases in China are expected to resume normal production capacity in April 2020 which is very encouraging. The Group will continue to work hard on ensuring the normal business development and achieving safe…